Opendata, web and dolomites

MultiDiag

Rapid, cost-effective, multiplex point of care diagnostic immunoassay system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MultiDiag project word cloud

Explore the words cloud of the MultiDiag project. It provides you a very rough idea of what is the project "MultiDiag" about.

point    size    parallel    immunoassays    confirm    takes    hours    modern    tested    near    decades    allergy    sensitive    infectious    laboratories    prepare    made    commercial    incorporated    pricing    route    disposable    multiplexed    clinical    healthcare    mean    first    accurate    care    patient    liquid    diseases    our    disease    competition    arrays    oncology    commercialise    quantitative    followed    contrast    plan    diagnoses    benefits    autoimmune    facilities    15    series    diagnostic    array    intend    feasibility    multiplex    rapid    inherent    lt    complete    reduce    biomarker    business    earliest    accurately    provides    opportunity    bench    retaining    initial    laboratory    stream    panels    cartridge    20min    lined    diagnosis    standard    disorders    sensitivity    market    handling    mainstay    tests    nalia    changed    assesses    perform    platform    whilst    manufacturable    cartridges    device    elisa    biomarkers    globally    accuracy    time    data    submit    quantification    central    dramatically   

Project "MultiDiag" data sheet

The following table provides information about the project.

Coordinator
NALIA SYSTEMS LIMITED 

Organization address
address: C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE
city: LONDON
postcode: NW9 8UA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.naliasystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NALIA SYSTEMS LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity. Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform. NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories. Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result. This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases. In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More